Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06414902
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
18F-AraG PETCT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
18F-AraG PETCT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participants response to treatment
Detailed Description:
Primary Objectives
Evaluate the ability of 18F-FAraG PET imaging to detect tumors in participants with esophageal cancer
Evaluate 18F-FAraG PET as a predictor of pathologic complete response
Secondary Objectives
Evaluate the correlation of 18F-FAraG PET with clinical characteristics
Evaluate the correlation of 18F-FAraG PET with scRNA-seq data
Evaluate tissue and blood biomarkers as predictors of treatment response and disease recurrence
Evaluate functional imaging with 18F-FAraG PET and tissue and blood biomarkers as predictors of overall survival and disease-free survival
Compare 18F-FAraG PET SUV update to the change in standard 18FDG-PET SUV parameters before and after chemoradiation
Evaluate the ability of 18F-FAraG PET imaging to detect tumors in participants with esophageal cancer
Evaluate 18F-FAraG PET as a predictor of pathologic complete response
Secondary Objectives
Evaluate the correlation of 18F-FAraG PET with clinical characteristics
Evaluate the correlation of 18F-FAraG PET with scRNA-seq data
Evaluate tissue and blood biomarkers as predictors of treatment response and disease recurrence
Evaluate functional imaging with 18F-FAraG PET and tissue and blood biomarkers as predictors of overall survival and disease-free survival
Compare 18F-FAraG PET SUV update to the change in standard 18FDG-PET SUV parameters before and after chemoradiation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2024-04295 | OTHER | NCI-CTRP Clinical Registry | None |